Table 1 Baseline characteristics of the study patients according to the tertiles of GLR (n = 496)
Variables | Tertile 1 (< 20.442, n = 165) | Tertile 2 (20.442–50.382, n = 165) | Tertile 3 (> 50.382, n = 166) | P-value |
|---|---|---|---|---|
Age (years) | 0.133 | |||
≤ 60 | 111 (67.273%) | 113 (68.485%) | 127 (76.506%) | |
> 60 | 54 (32.727%) | 52 (31.515%) | 39 (23.494%) | |
Sex | 0.003 | |||
Male | 117 (70.909%) | 135 (81.818%) | 142 (85.542%) | |
Female | 48 (29.091%) | 30 (18.182%) | 24 (14.458%) | |
Smoking | < 0.001 | |||
No | 123 (74.545%) | 102 (61.818%) | 91 (54.819%) | |
Yes | 42 (25.455%) | 63 (38.182%) | 75 (45.181%) | |
Drinking | 0.015 | |||
NO | 140 (84.848%) | 128 (77.576%) | 119 (71.687%) | |
Yes | 25 (15.152%) | 37 (22.424%) | 47 (28.313%) | |
HCC family history | 0.666 | |||
No | 142 (86.061%) | 147 (89.091%) | 147 (88.554%) | |
Yes | 23 (13.939%) | 18 (10.909%) | 19 (11.446%) | |
HBsAg | 0.744 | |||
Negative | 24 (14.545%) | 21 (12.727%) | 26 (15.663%) | |
Positive | 139 (84.242%) | 139 (84.242%) | 137 (82.530%) | |
NA | 2 (1.212%) | 5 (3.030%) | 3 (1.807%) | |
ALT (U/L) | 23.000 (8.000–101.000) | 28.000 (10.000–265.000) | 38.000 (10.000–605.000) | < 0.001 |
AST (U/L) | 24.000 (12.000–89.000) | 29.000 (14.000–159.000) | 40.500 (15.000–386.000) | < 0.001 |
ALP (U/L) | 77.058 (22.856) | 87.962 (29.539) | 116.245 (68.271) | < 0.001 |
HB (g/L) | 134.727 (15.461) | 135.273 (17.457) | 131.333 (20.427) | 0.096 |
PLT (10^9/L) | 153.073 (51.750) | 136.170 (57.049) | 124.476 (69.775) | < 0.001 |
AFP (ng/ml) | 0.071 | |||
≤ 20 | 70 (44.872%) | 82 (51.572%) | 62 (38.750%) | |
> 20 | 86 (55.128%) | 77 (48.428%) | 98 (61.250%) | |
Child–Pugh class | 0.065 | |||
A | 162 (98.182%) | 156 (94.545%) | 154 (92.771%) | |
B | 3 (1.818%) | 9 (5.455%) | 12 (7.229%) | |
Differentiation | 0.615 | |||
Well-moderate | 144 (91.139%) | 145 (90.062%) | 137 (87.821%) | |
Poor | 14 (8.861%) | 16 (9.938%) | 19 (12.179%) | |
Lymphovascular invasion | 0.224 | |||
No | 130 (78.788%) | 137 (83.030%) | 125 (75.301%) | |
Yes | 35 (21.212%) | 28 (16.970%) | 41 (24.699%) | |
ASA | 0.377 | |||
I | 19 (11.585%) | 13 (7.927%) | 19 (11.446%) | |
II | 137 (83.537%) | 135 (82.317%) | 136 (81.928%) | |
III | 8 (4.878%) | 16 (9.756%) | 11 (6.627%) | |
Operation time (min) | 140.745 (46.511) | 166.097 (58.854) | 177.175 (63.115) | < 0.001 |
Urine volume (ml) | 300.00 (0.000–1200.000) | 350.000 (20.000–3500.000) | 300.000 (50.000–2150.000) | 0.069 |
Bleeding volume (ml) | 200.000(5.000–1400.000) | 300.000 (20.000–3500.000) | 400.000 (20.000–5000.000) | < 0.001 |
Allogeneic blood | < 0.001 | |||
No | 156 (95.122%) | 146 (89.571%) | 122 (73.494%) | |
Yes | 8 (4.878%) | 17 (10.429%) | 44 (26.506%) | |
Tumor number | 0.864 | |||
Single | 154 (93.333%) | 154 (93.333%) | 157 (94.578%) | |
Multiple | 11 (6.667%) | 11 (6.667%) | 9 (5.422%) | |
TNM | 0.183 | |||
I | 122 (73.939%) | 128 (77.576%) | 114 (68.675%) | |
II | 43 (26.061%) | 37 (22.424%) | 52 (31.325%) | |
Tumor size (cm) | < 0.001 | |||
≤ 5 | 132 (80.000%) | 108 (65.455%) | 92 (55.422%) | |
> 5 | 33 (20.000%) | 57 (34.545%) | 74 (44.578%) | |
Recurrence | < 0.001 | |||
No | 120 (72.727%) | 93 (56.364%) | 84 (50.602%) | |
Yes | 45 (27.273%) | 72 (43.636%) | 82 (49.398%) | |